Cardiovascular profile of loratadine

Clin Exp Allergy. 1999 Jul:29 Suppl 3:197-9. doi: 10.1046/j.1365-2222.1999.0290s3197.x.

Abstract

The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.

Publication types

  • Review

MeSH terms

  • Animals
  • Cardiovascular System / drug effects*
  • Cation Transport Proteins*
  • DNA-Binding Proteins*
  • Drug Interactions
  • ERG1 Potassium Channel
  • Electrocardiography / drug effects
  • Ether-A-Go-Go Potassium Channels
  • Histamine H1 Antagonists / adverse effects*
  • Humans
  • Loratadine / adverse effects*
  • Potassium Channels / drug effects
  • Potassium Channels, Voltage-Gated*
  • Trans-Activators*
  • Transcriptional Regulator ERG

Substances

  • Cation Transport Proteins
  • DNA-Binding Proteins
  • ERG protein, human
  • ERG1 Potassium Channel
  • Ether-A-Go-Go Potassium Channels
  • Histamine H1 Antagonists
  • KCNH6 protein, human
  • Potassium Channels
  • Potassium Channels, Voltage-Gated
  • Trans-Activators
  • Transcriptional Regulator ERG
  • Loratadine